EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 22 January 2026

News

EFPIA Statement on the EU–Mercosur Free Trade Agreement
20 January 2026

While the agreement includes some progress for the innovative pharmaceutical sector, particularly through partial tariff... Read more

EFPIA statement following European Parliament plenary vote on the Critical Medicines Act
20 January 2026

EFPIA acknowledges today’s vote in the European Parliament plenary on the Critical Medicines Act (CMA). Read more

Blogs

From readiness to reality: preparing Europe for the next phase of Alzheimer’s care (Guest blog)...
20 January 2026

Europe has reached a turning point on Alzheimer’s disease, where scientific breakthroughs are no longer theoretical,... Read more

Europe has a choice to make

Clinical trials matter. They give patients the earliest access to new medicines, up to 5-10 years before launch and deliver €1-1.5bn to health systems every year. Yet in just five years, Europe has lost 60,000 clinical trial places.

Europe is at a crossroads: bring clinical trials back or let the gap grow.

Learn more here.

Events

2nd European Summit for Women Leaders in Life Sciences
10 March 2026 (Brussels, Belgium)

Get ready for C5’s 2nd Annual European Summit for Women Leaders in Life Sciences Law — two days of impactful discussions,... Read more

European Conference on Rare Diseases and Orphan Products (ECRD) 2026
03 June 2026 (Prague & Online)

The next ECRD will be held on 3 & 4 June 2026 in Prague and will be titled “Rare Diseases in a Changing & Competitive... Read more

What we are reading

Q&A Europe faces a pivotal moment in health innovation
On 22 January 2026 (POLITICO)

Pharma innovation is accelerating and Europe risks losing ground. In this Q&A, Takeda’s Jean-Luc Delay explains... Read more

Alzheimer Europe launches discussion paper and guidelines for the ethical use of technology...
On 21 January 2026 (Alzheimer Europe)

Alzheimer Europe has launched a discussion paper on the use of technology for and by people with dementia. This document... Read more

Human medicines in 2025
On 15 January 2026 (EMA)

In 2025, EMA recommended 104 medicines for marketing authorisation. Of these, 38 had a new active... Read more

You can’t eliminate what you don’t measure: The data gap on HPV vaccination
On 11 December 2025 (Vaccines Today)

Vaccines are among the most powerful tools in modern medicine, preventing millions of deaths every year. Human Papillomavirus... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu